Physician profile
Larry L Ware
NPI 1861479685
$1,728.50
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $592 · 2021: $788.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $276.57 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.85 | 2019-2021 | |
| Pfizer INC. | $185.30 | 2019-2021 | |
| Glaxosmithkline, LLC. | $158.70 | 2019-2021 | |
| Novo Nordisk INC | $123.31 | 2019-2021 | |
| Abbvie INC. | $94.59 | 2021 | |
| Amarin Pharma, INC. | $89.92 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.61 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $79.07 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $72.91 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $52.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.73 | 2020 | |
| Esperion Therapeutics, INC. | $37.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.28 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $31.86 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $30.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.22 | 2021 | |
| Bausch Health US, LLC | $16.23 | 2019 | |
| Hikma Pharmaceuticals USA | $14.27 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.04 | 2019 | |
| Astellas Pharma US INC | $14.00 | 2020 | |
| Dexcom, INC. | $13.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.26 | 2019 | |
| Allergan, INC. | $11.93 | 2020 | |
| Amgen INC. | $11.75 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.